EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Clinical performance validation of the STANDARD G6PD test: A multi-country pooled analysis

Wondimagegn Adissu, Marcelo Brito, Eduardo Garbin, Marcela Macedo, Wuelton Monteiro, Sandip Kumar Mukherjee, Jane Myburg, Mohammad Shafiul Alam, Germana Bancone, Pooja Bansil, Sampa Pal, Abhijit Sharma und 17 weitere

PLOS Neglected Tropical Diseases · 2023

DOI: 10.1371/journal.pntd.0011652 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS Neglected Tropical Diseases, 2023. Verfasst von Wondimagegn Adissu und 28 weiteren Autor:innen. Beteiligte Einrichtung: School of Medical Laboratory Sciences, Jimma University, Jimma, Ethiopia. Hauptthemen laut MEDLINE: Glucosephosphate Dehydrogenase Deficiency, Antimalarials, Malaria, Vivax. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust, Foreign, Commonwealth and Development Office, Bill and Melinda Gates Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Screening for G6PD deficiency can inform disease management including malaria. Treatment with the antimalarial drugs primaquine and tafenoquine can be guided by point-of-care testing for G6PD deficiency. Methods and findings Data from similar clinical studies evaluating the performance of the STANDARD G6PD Test (SD Biosensor, South Korea) conducted in Bangladesh, Brazil, Ethiopia, India, Thailand, the United Kingdom, and the United States were pooled. Test performance was assessed in a retrospective analysis on capillary and venous specimens. All study sites used spectrophotometry for reference G6PD testing, and either the HemoCue or complete blood count for reference hemoglobin measurement. The sensitivity of the STANDARD G6PD Test using the manufacturer thresholds for G6PD deficient and intermediate cases in capillary specimens from 4212 study participants was 100% (95% Confidence Interval (CI): 97.5%–100%) for G6PD deficient cases with 60% on the reference assay. The negative predictive value for females with G6PD activity >60% was 99.6% (95% CI 99.1%–99.8%) on capillary specimens. Sensitivity among 396 P . vivax malaria cases was 100% (69.2%–100.0%) for both deficient and intermediate cases. Across the full dataset, 37% of those classified as G6PD deficient or intermediate resulted from true normal cases. Despite this, over 95% of cases would receive correct treatment with primaquine, over 87% of cases would receive correct treatment with tafenoquine, and no true G6PD deficient cases would be treated inappropriately based on the result of the STANDARD G6PD Test.

Conclusions

The STANDARD G6PD Test enables safe access to drugs which are contraindicated for individuals with G6PD deficiency. Operational considerations will inform test uptake in specific settings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glucosephosphate Dehydrogenase DeficiencyAntimalarialsMalaria, VivaxFemaleHumansPrimaquineRetrospective Studies

Substanzen

PrimaquineAntimalarials

Autor:innen und Institutionen

  • School of Medical Laboratory Sciences, Jimma University, Jimma, Ethiopia.
  • Clinical Trial Unit, Jimma University, Jimma, Ethiopia.
  • Fundação de Medicina Tropical Dr Heitor Vieira Dourado (FMT-HVD), Manaus, Amazonas, Brazil.
  • Universidade do Estado do Amazonas, Manaus, Amazonas, Brazil.
  • Centro de Pesquisa Em Medicina Tropical (CEPEM), Porto Velho, Rondônia, Brazil.
  • National Institute of Cholera and Enteric Diseases, Kolkata, India.

ORCID-Profile: Gonzalo J Domingo, Emily Gerth-Guyette

Förderung

  • Wellcome Trust
  • Foreign, Commonwealth and Development Office
  • Bill and Melinda Gates Foundation
  • Bill & Melinda Gates Foundation

Zitieren

APA

Adissu, W., Brito, M., Garbin, E., Macedo, M., Monteiro, W., Mukherjee, S. K., Myburg, J., Alam, M. S., Bancone, G., Bansil, P., Pal, S., Sharma, A., Zobrist, S., Bryan, A., Chu, C. S., Das, S., Domingo, G. J., Hann, A., Kublin, J., …, & Gerth-Guyette, E. (2023). Clinical performance validation of the STANDARD G6PD test: A multi-country pooled analysis. PLOS Neglected Tropical Diseases. https://doi.org/10.1371/journal.pntd.0011652

Vancouver

Adissu W, Brito M, Garbin E, Macedo M, Monteiro W, Mukherjee SK, et al. Clinical performance validation of the STANDARD G6PD test: A multi-country pooled analysis. PLOS Neglected Tropical Diseases. 2023. doi:10.1371/journal.pntd.0011652

BibTeX
@article{Adissu2023,
  author = {Adissu, Wondimagegn and Brito, Marcelo and Garbin, Eduardo and Macedo, Marcela and Monteiro, Wuelton and Mukherjee, Sandip Kumar and Myburg, Jane and Alam, Mohammad Shafiul and Bancone, Germana and Bansil, Pooja and Pal, Sampa and Sharma, Abhijit and Zobrist, Stephanie and Bryan, Andrew and Chu, Cindy S and Das, Santasabuj and Domingo, Gonzalo J and Hann, Amanda and Kublin, James and Lacerda, Marcus V G and Layton, Mark and Ley, Benedikt and Murphy, Sean C and Nosten, Francois and Pereira, Dhélio and Price, Ric N and Talukdar, Arunansu and Yilma, Daniel and Gerth-Guyette, Emily},
  title = {Clinical performance validation of the STANDARD G6PD test: A multi-country pooled analysis},
  journal = {PLOS Neglected Tropical Diseases},
  year = {2023},
  doi = {10.1371/journal.pntd.0011652}
}
Kostenlos starten →